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Abstract  
AIM: To assess the long-term effectiveness of hepatitis B virus vaccine and the need for a booster 
dose among children who received three doses of vaccine during infancy in Red Sea Governorate.  
METHODS: A cross-sectional study was performed. Interviews with children (9 months to 16 years) 
and parents were done. Blood samples to assess Hepatitis B markers were tested. Children 
showing no seroprotection received a booster dose to assess their anamnestic response after four 
weeks and one year later.  
RESULTS: None of the participants had evidence of chronic Hepatitis B. The seroprotection rate 
was 23.3% and it significantly decreased with age. Multivariate logistic analysis revealed that older 
age was the significant predicting variable for having no seroprotective level, while baseline anti-
HBs level < 3.3 IU/L was the predicting variable for not developing early anamnestic response or 
loss of late anamnestic response.  
CONCLUSION: Long-term immunity persists among children who received complete series of 
hepatitis B vaccination during infancy even in absence or reduction of anti-HBs over time. 
Therefore, a booster dose is not necessary to maintain immunity till the age of sixteen. 
 
 
 
 
 
Introduction 
 
HBV infection is a leading cause of acute and 
chronic liver disease, cirrhosis and hepatocellular 
carcinoma worldwide. WHO estimates that globally, 
about 2 billion people have been infected with 
hepatitis B virus, more than 350 million are chronically 
infected, and nearly 1 million die every year from 
acute or chronic sequelae of primary infection with the 
disease [1, 2]. In Egypt, 75%–85% of patients with the 
chronic liver disease have HBV or HCV infection as a 
contributing cause [3]. 
Mass vaccination of neonates and pre-
school children has been strongly recommended by 
the WHO [4, 5]. Hepatitis B vaccines are highly 
effective and safe and the public should be educated 
about the importance and necessity of hepatitis B 
prevention by vaccination [6, 7]. 
It has been demonstrated that 90–99% of 
healthy neonates, children, adolescents, and adults 
develop protective levels of anti-HBs following a 
standard vaccination course with hepatitis B vaccine. 
Serum levels of anti-HBs ≥ 10 IU/L are considered to 
be protective against HBV infection [7-9]. Loss of 
detectable concentrations of antibodies (anti-HBs) to 
hepatitis B surface antigen (HBsAg) does not 
necessarily indicate loss of immunity. The presence of 
HBV-specific immune memory can be demonstrated 
by administering a challenging (booster) dose of 
vaccine and measuring anti-HBs response. A rapid 
increase in anti-HBs represents an anamnestic 
response and is considered to indicate the presence 
of HBV-specific immune memory [10]. 
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In Egypt, HBV vaccination was included in 
1992 in the Expanded Program on Immunization (EPI) 
with injections at 2, 4 and 6 months of age using the 
recombinant vaccine. The Ministry of Health and 
Population conducted a wide range of prophylactic 
strategies to control viral hepatitis. It was reported that 
the prevalence of hepatitis B surface antigen (HBsAg) 
positivity among healthy individuals decreased from 
10.1% in 1985 to 1.18% in 2008, and the frequency of 
acute HBV infection as a cause of symptomatic 
hepatitis decreased significantly from 43.4% in 1983 
to 28.5% in 2002 [11, 12].  
The aim of the present study is to assess the 
long-term effectiveness of HBV vaccine and the need 
for a booster dose among fully vaccinated children 
during infancy in Red Sea Governorate. 
 
 
Subjects and Methods 
 
The present study is a part of a national 
community based multi-stage cluster sampling design 
carried out in the period from July 2010 to June 2013 
in 6 governorates representing all geographic regions 
of Egypt. For sampling process and cluster selection, 
probability proportional to size sampling was used. 
The sample frame for the current survey was based 
on the most recent population census 2006. 
According to the population size of each governorate, 
the number of participating clusters was identified in 
each governorate. First, implicit stratification by 
geographic location in each governorate, lists of 
shakhas, medinas, and villages were arranged in 
serpentine order geographically. This stratification 
was done independently for urban and rural areas. A 
sampling interval was calculated and accordingly, a 
random number was selected using a table of random 
numbers. From these lists, areas such as villages or 
city blocks were selected. In each selected area, lists 
of child health center (MCH), kindergarten and school 
facilities were identified and 5 facility clusters were 
randomly selected. 
The current work presented the part of the 
project results concerning Red Sea Governorate. 
From this governorate, 189 children from Hurghada 
were recruited. The study was conducted at facility 
levels, where 5 facilities (one maternal and child 
health center (MCH) or health unit, one kindergarten 
and 3 schools (1 primary, 1 preparatory and 1 
secondary school) were randomly selected from each 
area according to the age of the targeted children. 
The study protocol was approved by the 
ethical committees of Ministry of Health, National 
Research Center and Ministry of Education. A close-
ended questionnaire was designed and tested. For 
quality assurance, training sessions for supervisors, 
interviewers and Ministry of Health staff in Red Sea 
governorate were carried out. Peel-off barcode sheets 
were prepared and used for easy tracking of blood 
samples and laboratory results. Inclusion criteria were 
children aged from 9 months to 16 years and had 
received the full 3 compulsory doses of HBV vaccine 
during infancy. Signed written consents were obtained 
from each guardian Face to face interview was carried 
out with the parents or caretakers of the children. 
Adolescents above 10 years were also interviewed 
after their verbal assents which were obtained in the 
presence of their parents or class teachers. The 
questionnaire was used to collect data about child 
age, sex, date of birth and other demographic and 
socioeconomic variables. Data were also collected 
concerning children's' HBV vaccination and the 
available vaccination cards were revised for date and 
dose intervals of HBV vaccine. Socioeconomic status 
(SES) was determined according to Fahmy and El 
Sherbiny [13]. It depends on parents’ education, 
maternal working status, water source, sewage 
disposable, and availability of electricity and some 
modification of family income. Non-responders for the 
booster dose were further given 2 additional doses of 
HBV vaccine with 2 months interval in between. 
Out of 88 children proved to have non-
seroprotective levels, 45 children participated and 
accepted to receive a booster dose of 10 μg 
monovalent Euvax HB vaccine intramuscularly in the 
front of the left thigh for children < 3 years and in the 
deltoid muscle for older children. A blood sample was 
withdrawn from each child for quantitative detection 
of anti-HBs one month and one year post–booster in 
order to assess their early and late anamnestic 
responses respectively. An anamnestic response was 
defined as rising in anti-HBs to ≥10 IU/L [14]. Three 
children who did not develop post-booster anti-
HBs level ≥ 10 IU/L were then offered two additional 
doses of Euvax HB vaccine (2nd vaccination series) 1 
and 6 months post booster. One month later, a blood 
sample was withdrawn from only 2 children for 
quantitative detection of anti-HBs to assess their 
immune response. 
 
Blood sampling and Laboratory Analysis 
About 3-5 ml blood sample was withdrawn 
aseptically from each participant. Serum samples 
were aliquoted into two labeled sterile cryo tubes and 
were stored at –20°C until laboratory examination. 
HBV markers detection was carried out in the Virology 
lab in the Microbiology Department,Faculty of 
Medicine (for Girls), Al-Azhar University, Cairo, Egypt. 
It was carried out using commercially available 
enzyme-linked immunoassays (ELISA, DiaSorin-
Italy) and according to the manufacturer instructions. 
Quantitative detection of serum anti-HBs and 
qualitative determination of serum Total HBV core 
antibody (anti-HBc) and hepatitis B surface antigen 
(HBsAg) was assessed. According to international 
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standards, anti-HBs ≥ 10 IU/L was considered to be 
protective against HBV infection [14, 15]. Vaccines 
that developed an anti HBs level between 10-100 IU/L 
after the full vaccination dose are referred to as low 
responders while those above 100 IU/L are good 
responders [16]. Sero-positivity is defined as cut-
off anti-HBs of 3.3 IU/L [17]. Breakthrough infection 
was defined as anti-HBs seropositivity in vaccinated 
subjects who were not chronically infected [18]. 
 
Data analysis and presentation 
Data entry was carried out on excel sheet and 
statistical analysis was performed using SPSS 
software program version 18.0 (SPSS Inc., Chicago). 
The geometric mean titer (GMT) was calculated to 
indicate the central tendency of anti-HBs titers in 
consideration of the skewed distribution of anti-
HBs level. For the calculation of the GMT, children 
who had an undetectable anti-HBs titer were assigned 
a nominal serum anti-HBs titer value of 0.05 IU/l [13]. 
The w2-test was performed for qualitative data and 
was presented by numbers and percentages. The t-
test was performed for comparison between two 
means and one-way analysis of variance for more 
than two means. When data were not normally 
distributed, Mann-Whitney U test was used. The 
multivariate logistic analysis was performed to predict 
the risk factors significantly associated with non 
seroprotection and non-development of early and late 
anamnestic response. P value was considered 
statistically significant when its value was less than 
0.05 and considered statistically highly significant 
when its value was less than 0.01. 
 
 
Results 
 
The total number of studied children was 189 
(100 boys and 89 girls) aged 9 months to 16 years 
with a mean age of 9.6 years. None of the participants 
had an evidence of chronic HBV or breakthrough 
infection. Table 1 shows that the non-
seroprotection level significantly increased with age (it 
was 17.2% for the age group < 5 years and 66% for 
the age group >10 years, P < 0.05). There was no 
significant difference in the seroprotection level as 
regards gender, socioeconomic status, and other 
studied variables. 
Only 45 children with non-seroprotection level 
received the booster dose and 93.4% of them 
developed an anamnestic response. Figure 1 
presents the baseline seroprotection rate and post-
booster anamnestic response rate among the studied 
children. At baseline, out of 189 studied children, only 
44 (23.3%) had a good level of seroprotection (anti-
HBs ≥ 100 IU/L) and 88 (46.6%) had a non-
seroprotective level (< 10IU/L). As regards early post-
booster anamnestic response, 75.6% developed a 
good anamnestic response, 17.8% developed low 
anamnestic response (10-99 IU/L) and 6.7% were 
non-responders. 
Table 1: Sero-protection rate among the studied children 
Risk Factor 
Total 
n= 189 
Baseline anti-HBs level (IU/L) 
Non sero-
protection 
Anti-HBs <10 
n= 88 
n (%) 
Sero-protection 
Anti-HBs ≥10 
n= 101  
n (%) 
 
 
P value 
Gender  
Boys  
Girls 
 
100 
89 
 
46   (46.0) 
42   (47.2) 
 
54     (54.0) 
47     (52.8) 
 
0.870 
Age group 
<5years 
5-10years 
>10years 
 
58 
37 
94 
 
10   (17.2) 
16   (43.2) 
62   (66.0) 
 
48     (82.8) 
21     (56.8) 
32     (34.0) 
 
 
< 0.001 
Socioeconomic status 
Very low 
Low  
Middle  
High 
 
28 
37 
47 
70 
 
17   (60.7) 
18   (48.6) 
22   (46.8) 
28   (40.0) 
 
11     (39.3) 
19     (51.4) 
25     (53.2) 
42     (60.0) 
 
 
 
0.317 
HAZ 
> -2 
≤ -2 
 
159 
22 
 
76    (47.8) 
  8    (36.4) 
 
83      (52.2) 
14      (63.6) 
 
0.736 
WAZ 
> -2 
≤ -2 
 
176 
3 
 
81    (46.0) 
  1    (33.3) 
 
95      (54.0) 
  2      (66.7) 
 
0.189 
Lactation  
Breast fed  
Artificially fed 
 
134 
29 
 
 57     (42.5) 
 17     (58.6) 
 
77       (57.5) 
12       (41.4) 
 
0.272 
History of hospital admission 
Yes 
No 
 
58 
131 
 
 33     (56.9) 
 55     (42.0) 
 
25       (43.1) 
76       (58.0) 
 
0.058 
History of abscess incision 
Yes 
No 
 
12 
174 
 
   5     (41.7) 
 82     (47.1) 
 
  7       (58.3) 
92       (52.9) 
 
0.714 
HAZ = height for age Z score; WAZ = weight for age Z score. 
 
Out of 42 children who developed early, 
anamnestic response 41 (97.6%) were followed up 
one year later to assess the persistence of response 
(late anamnestic response). It was found that 31 
children (75.6%) still retained their anamnestic 
response (anti-HBs ≥10IU/L) while 10 children 
(24.4%) had lost their protective level.  
 
Figure 1: Baseline seroprotection and early anamnestic response 
rates among the studied children 
 
Meanwhile, the two children who received the 
2nd vaccination series developed a good level of 
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immune response (anti-HBs ≥100 IU/L). Both were 
boys aged 11 years. 
Table 2: Anamnestic response and anti-HBs GMT in relation 
to gender, age, and pre-booster level 
Risk Factor 
Baseline anti-HBs 
Early Anamnestic 
Response 
Late Anamnestic 
Response 
N = 189 
GMT ± SD 
N = 45 
GMT ± SD 
N = 41 
GMT ± SD 
Gender  
Boys  
Girls 
P value 
 
9.8 ± 13.5 
12.1 ± 14.9 
0.589 
 
209.6 ± 12.2 
249.0 ± 9.2 
0.624 
 
95.5 ± 21.3 
39.3 ± 2.3 
0.117 
Age group 
≤10 years 
>10 years 
P value 
 
45.7 ± 9.5 
3.6 ± 10.9 
<0.001 
 
227.0 ± 3.9 
228.2 ± 12.4 
0.189 
 
38.8 ± 12.6 
67.6 ± 25.5 
0.409 
Pre-booster level 
< 3.3 IU/L 
≥ 3.3 IU/L 
P value 
 
1.2 ± 1.1 
6.0 ± 1.4 
0.001 
 
848.6 ± 1.3 
64.3 ± 18.0 
0.004 
 
10.9 ± 35.7 
37.5 ± 31.2 
0.375 
GMT=geometric mean titre. 
 
Table 2 presents baseline, early and late 
anamnestic response anti-HBs GMT in relation to 
gender, age, and pre-booster level. There was no 
difference between both sexes as regard pre-
booster and post- booster (early and late anamnestic 
response) GMT anti-HBs. While children aged ≤ 10 
years had significantly higher pre-booster anti-
HBs GMT than older children, post-booster (early and 
late) GMT anti- HBs did not differ among both age 
groups. When pre-booster non-seroprotection anti-
HBs levels were divided into seronegative (< 3.3 IU/L) 
and seropositive (≥ 3.3 IU/L), the post-booster early 
anamnestic response GMT was significantly higher 
among children with seropositive level of anti-
HBs than among those with seronegative level of anti-
HBs (848.6 ± 1.3 & 64.3 ± 18.0 respectively) P = 
0.004. However, there was no statistically significant 
difference between both groups for late anamnestic 
response GMT. 
Table 3: Predictors of not seroprotection, early and late 
anamnestic responses using logistic analysis 
Variables AOR 95% CI P value 
Lower Upper 
At Baseline 
Age group 
< 5 years 
5-10 years 
>10 years 
 
® 
3.616 
8.509 
 
 
1.363 
3.648 
 
 
9.592 
19.848 
 
 
  0.010 
< 0.001 
Early Anamnestic Response 
Baseline anti-HBs  level 
≥ 3.3 IU/L 
< 3.3 IU/L 
 
 
® 
4.7 
 
 
2.1 
 
 
10.4 
 
 
< 0.001 
Late Anamnestic response 
Baseline anti-HBs  level 
≥ 3.3 IU/L 
< 3.3 IU/L 
 
 
® 
2.0 
 
 
 
1.4 
 
 
 
3.0 
 
 
 
< 0.001 
®: reference group; AOR: adjusted odds ratio; CI: confidence interval. 
 
 
Multivariate logistic analysis revealed that 
older age was the only significant predicting variable 
for having no seroprotective level, with AOR = 3.6 and 
8.5 among children aged 5-10 and older age 
respectively compared to those < 5 years, P < 0.01. 
The significant predicting variable for not developing 
an early anamnestic response or loss of late 
anamnestic response was baseline anti-HBs level < 
3.3 IU/L with AOR 4.7 & 2.0 respectively and P<0.001 
for both (Table 3). 
 
 
Discussion 
 
Universal infant vaccination will be the key to 
the elimination and subsequent eradication of 
hepatitis B. Elimination and eradication of hepatitis B 
require long-term commitment all over the world to 
continue the vaccination. Further progress towards 
the elimination of HBV transmission will require 
sustainable vaccination programs with improved 
vaccination coverage [6, 19]. 
In the current study, 189 studied children 
received three doses of HB vaccine during infancy 
and none of them had an evidence of chronic HBV or 
breakthrough infection. The overall seroprotection rate 
among all studied children was 53.4%. This rate is 
similar to that of a study carried out in Dakahlya Egypt 
where seroprotection rate was 57.7% [20] and in 
Turkey [21]. However, higher percentages were 
reported among Chinese, Italian and Iranian children 
(66.4%,64% & 81% respectively) [9,22,23]. The 
present study also found that 82.8% of participants 
aged less than 5 years were HBV seroprotected and 
the seroprotection rate significantly decreased with 
age which is in agreement with Yazdanpanah et al, 
[24]. Lower percentages (68.1%) were reported by 
Zhu et al for the same age group [9]. For older 
children ≥ 6 years, Liop et al and Behjati et al reported 
seroprotection rates were >70% [25, 26]. 
The seroprotection rate was higher among 
boys (54.0%) than girls (52.8%) and among children 
with higher socioeconomic status (60.0%) compared 
with others with very low socioeconomic status 
(39.4%), but with no statistically significant difference. 
Similarly, no statistically significant differences were 
reported as regards gender [5, 21, 22, 24]. However, 
Sami et al found that in Gharbeya Governorate in 
Lower Egypt among 762 children, the non 
seroprotection rate was significantly higher among 
girls (50.1%) compared to boys (33.6%) (P<0.0005), 
while the seroprotection rate was found to be 
significantly higher among high socioeconomic level 
individuals (61.2%) compared to those of very low 
class (49.6%) (P < 0.05) [27]. 
Another Egyptian study carried out on 64 
children found that the nonsero-protective rate of anti-
HBs was significantly higher among girls than boys 
aged > 6 years, while no statistical difference was 
found among children < 6 years [28]. 
The present study showed that 46.6% of 
studied children had non-seroprotective levels of anti-
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HBsat baseline and 93.4% of those receiving the 
booster dose developed an anamnestic response. 
Seventy-five percent of them developed good 
anamnestic response (anti-HBs ≥ 100 IU/L) and 6.7% 
were non-responders. Similarly, in Egypt, it was found 
that 91.7% of non-seroprotected children developed 
anamnestic response and 77.8% of them reported 
good response [27]. Moreover, Eldesoky et al found 
that 97.2% of the non-seroprotected children 
developed good anamnestic response [7]. A Turkish 
and an Italian study also reported that over 95% 
of non-seroprotected children developed an 
anamnestic response post booster [21, 22]. A lower 
percentage of children developed a post-
booster anamnestic response in Iran (78.1%) and in 
Taiwan [24, 29]. Booster doses of hepatitis B vaccine 
after primary vaccination in immune competent 
individuals are currently not recommended by either 
the WHO or the European Consensus group on 
Hepatitis B Immunity. The decrease of antibody 
concentrations below seroprotection level or even 
below detection levels is not considered as an 
indicator of loss of protection [30]. The real threat may 
emerge when the vaccinated subjects begin to 
engage in high-risk behaviors for HBV transmission in 
areas of high endemicity. Boosters for certain high-
risk groups or for individuals living in the areas of high 
endemicity may be a reasonable alternative [31-33]. 
In this study, post booster anamnestic was 
detected among 100% of non-seroprotected children 
having pre-booster level ≥ 3.3 IU/l compared to only 
90.3% of those having pre-booster level < 3.3 IU/l (P > 
0.05). Similarly but to a less extent, Steiner et al, 
reported that 90.5% of children who had anti-
HBs antibody concentrations > 3.3 IU/l reached the 
seroprotection level after receiving the booster dose 
compared to 81.0% of seronegative children [34]. 
In the current study, girls had higher pre-
booster and post-booster anti-HBs GMT compared 
with boys but with no statistically significant difference 
between both sexes (P > 0.05]. While children aged ≤ 
10 years had significantly higher pre-booster anti-
HBs GMT than those aged >10 years (P < 0.05], but 
there was no difference between both age groups in 
the post-booster anti-HBs GMT. These results are 
similar to those of other studies in Alaska, Turkey, and 
Iran which found that pre-booster anti-HBs GMT 
significantly decreased with age [10, 21, 24). 
However, in two Iranian studies, it was found that 
the post-booster anti-HBsGMT among girls was 
significantly higher than among boys (P < 0.05] [23, 
24]. The statistically significant difference between the 
mean antibody concentration before and after the 
booster dose shows the vigorous response of the 
immune system to the booster and suggests that the 
immunologic memory is good [24]. 
In the current study, 100% of the children ≤ 10 
years and 91.1% of adolescents developed 
anamnestic response (P > 0.05). Similarly, in Alaska, 
99% of children and 83% of adolescents [10] and 
100% of children in Taiwan [32] developed an 
anamnestic response to a booster dose. Similar 
results were also reported by [21, 24]. They also 
found that there was no significant difference in post-
booster anamnestic response rate as regards age. In 
contrast, the anamnestic response rate in Alaskan 
children decreased according to increasing age [10]. 
In the current study, the anamnestic response 
rate to the booster dose did not vary between boys 
and girls (91.3% and 95.5% respectively, P > 0.05). 
Similarly, in Gharbeya governorate, the anamnestic 
response rate was 90.1% among boys and 92.5% 
among girls, P > 0.05 [27]. On the contrary, Su et al 
found that Taiwanese adolescent females always had 
a greater anamnestic response rate than males (P < 
0.001) [35]. 
In the present study, 75.6% of children still 
retained their anamnestic response after one year 
post- booster. This was also found in a study in 
Gambia where 80% of boosted participants still had 
detectable antibodies [8] and in Canada where 99.3% 
of subjects in the Engerix-B 10 [mu]g (EB) group and 
100% in the Recombivax-HB 2.5 [mu]g (RB) group 
had detectable anti-HBs one year after the booster 
[31]. 
In this study after the booster dose was 
administered, 6.7% of children were non-responders 
and two out of the three children who failed to 
generate an early anamnestic response after 
receiving the booster dose, were offered another two 
doses of recombinant HBV vaccine. While 3% of 
Italian children and 4% of Italian recruits remained 
negative for anti-HBs, they offered to complete the 
second course of vaccination with two additional 
vaccine doses given at 1 and 6 months after the first 
booster injection [22]. Also, 3% of boosted participants 
in Gambia did not mount a detectable antibody 
response following a booster dose of HBV [8]. 
Samandari et al and Su et al reported that 28.7% and 
31% of Alaskan and Taiwanese adolescents 
respectively did not respond to a booster dose. [10, 
35] 
Logistic analysis for determining predictors of 
not seroprotection revealed that older age was the 
only significant predicting variable for having no 
seroprotective level while significant predicting 
variable for not developing an early anamnestic 
response or loss of late anamnestic response was 
baseline anti-HBs level < 3.3 IU/L. On the contrary, 
there was no significant difference as regards HBV 
booster non-response in subjects below or above 16 
years of age in a study by Lu et al [32.] In another 
study by Wang and Lin, risk of non-response to 
booster vaccination was highest among adolescents 
who smoked cigarettes and chewed betel- quid [36]. 
The study concluded that long-term immunity 
exists among children who had complete series of 
hepatitis B vaccination during infancy even in the case 
of reduced or absent anti-HBs over time. HBV vaccine 
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is highly protective against HBV infection as 
evidenced by the absence of HBV infection in the 
vaccinated groups. The longer the time lapse after 
vaccination, the lower the seroprotection rate and the 
lower the mean anti-HBs. More than 93% of 
vaccinated individuals who lost protective levels of 
antibody developed a rapid anamnestic response 
when boosted and this indicates the presence of 
immune memory. Therefore, using routine booster 
doses of hepatitis B vaccine is not necessary to 
sustain at least 16 years of protection in immunized 
individuals. 
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